Human estrogen receptor ␣ (hER␣) and human androgen receptor exhibit exquisite ligand specificity, which underlies their remarkable ability to effect ligand-regulated gene transcription in a highly distinctive and specific manner. Here we used a directed evolution approach to create hER␣ variants with enhanced androgen specificity and affinity with the goal to better understand the molecular basis of ER ligand specificity and the evolutionary mechanism of nuclear receptors. We developed a sensitive yeast two-hybrid system to screen for hER␣ variants with increased transactivation potency toward testosterone. After two rounds of directed evolution, we identified five hER␣ variants with dramatically improved transactivation potency toward testosterone in both yeast and mammalian cells. These variants showed up to 7,600-fold improvement in the binding affinity for testosterone and only slightly reduced affinity toward 17␤-estradiol. Detailed analysis of these evolved variants and a few site-directed mutants generated de novo led to several unexpected findings including the following. 1) Only two beneficial mutations were needed to create hER␣ variants with near nanomolar affinity for testosterone. 2) Some beneficial mutations were synergistic, context-dependent, or nonadditive. 3) Of the five identified beneficial mutations, four of them were not in the ER ligand binding pocket and yet exerted important action on ligand specificity. 4) The single ligand-contacting mutation E353Q plays a dominant role in discriminating androgens and estrogens. These results, viewed in conjunction with the ligand exploitation model of nuclear receptor evolution, suggest that the mutation E353Q may represent a key event in the evolution of androgen receptors from an ancestral estrogen receptor and that ligand promiscuity may play an important role in the creation of new nuclear receptors via divergent evolution.
The estrogen receptor (ER) 1 and androgen receptor (AR) belong to the steroid hormone nuclear receptor superfamily that regulates hormone-responsive genes in a ligand-inducible manner (1) . Like other members of this nuclear receptor superfamily, the ER and AR have three modular structural domains: an amino-terminal ligand-independent transactivation domain, a central DNA binding domain, and a carboxy-terminal ligand binding domain (LBD). The LBD of either ER or AR interacts specifically with its physiological ligand and contains a dimerization function and a ligand-dependent activation function AF-2 (2-5). Interestingly, despite their low sequence homology (Ͻ20%), the ER LBD and the AR LBD share a similar structural motif consisting of 12 ␣-helices arranged in an antiparallel sandwich motif (Figs. 1A and 6A).
Both the ER and the AR are of particular interest because of their important roles in the growth, differentiation, metabolism, reproduction, and morphogenesis of higher organisms and humans and their association with several human diseases. Estrogens such as 17␤-estradiol (E 2 ) (Fig. 1B) , acting through the ER␣ or ER␤, regulate the differentiation and maintenance of neural, skeletal, reproductive, and cardiovascular tissues. The regulation of ER␣ activity plays a critical role in osteoporosis, cardiovascular disease, and breast cancer (3, 6) . Androgens and their receptors exert crucial actions in male physiology and pathology. The binding of male sex steroids 5␣-dihydrotestosterone (DHT) and testosterone (T) (Fig.  1B) to the AR initiates male sexual differentiation and development (7) . Mutations in the human AR LBD have been linked to several diseases such as prostate cancer and the androgen insensitivity syndrome (3) . Thus, considerable effort has been directed at elucidating the molecular basis of ligand specificity of the ER and AR LBDs.
The ligand specificity and sensitivity of the ER or AR toward its physiological ligand are extremely high. Both the AR and the ER bind their physiological ligands with subnanomolar affinity, and a small difference in the ligand structure can have a dramatic effect on ligand binding affinity. For example, although the chemical structures of testosterone and E 2 differ only slightly in the A-ring region (Fig. 1B) , the affinity of human ER␣ for testosterone is Ͼ10,000-fold weaker than that for E 2 (this work), whereas the affinity of human AR for E 2 is 44-fold weaker than that for testosterone (8) . Comparison of the crystallographic structures of the human ER␣ LBD (hER␣ LBD) complexed with E 2 and the human AR LBD (hAR LBD) complexed with testosterone indicates that the majority of the residues (14 of 20) interacting with the ligand are different between the ER and the AR (Fig. 1A) . Thus, we have been intrigued by the structural features of hER␣ and hAR that underlie their ability to discriminate E 2 from testosterone. Prior site-directed mutagenesis studies have indicated that the hER␣ residue Glu-353 plays a significant role in discriminating estrogens from androgens (9) . However, that single mutation alone cannot account for the observed difference in ligand affinity and specificity between the ER and AR. To gain a further understanding of the interactions between the receptor and ligand, we have taken a new approach, directed evolution.
Directed evolution is a powerful tool for engineering proteins with improved functions, such as solubility, stability, affinity, and activity (10, 11) . Here we report the application of directed evolution to engineer hER␣ variants with up to 7,600-fold improvement in the binding affinity toward testosterone. Strikingly, these evolved hER␣ variants exhibited only slightly reduced binding affinity (1.5-3-fold) to E 2 and contained only two or three amino acid substitutions in the LBD. Further biochemical and structural analysis of these evolved ER variants provided new insights into the molecular basis of ER ligand specificity and the evolutionary mechanism of steroid receptors.
EXPERIMENTAL PROCEDURES
Reagents-Cell culture media were purchased from Invitrogen. Calf serum was obtained from HyClone Laboratories, Inc. (Logan, UT), and fetal calf serum was purchased from Atlanta Biologicals (Atlanta, GA). The luciferase assay system was from Promega Corp. (Madison, WI). The 17␤-estradiol, testosterone, dihydrotestosterone, and isopropyl-␤-D-thiogalactopyranoside were from Sigma. All restriction enzymes and DNAmodifying enzymes were obtained from New England BioLabs (Beverly, MA oligonucleotide primers were obtained from Integrated DNA Technologies (Coralville, IA).
Plasmid Construction-pCMV5-ER␣ plasmid containing the wild type full-length hER␣ cDNA (12) was first digested with EagI and BamHI and then treated with T4 DNA polymerase to form blunt ends at both termini followed by ligation into the EcoRI site (also treated with T4 DNA polymerase) of pBD-GAL4-Cam vector (Stratagene) to form pBD-GAL4 hER␣ containing hER␣ amino acids 312-595. pGAD424 SRC-1 containing the full-length SRC-1 was constructed as described elsewhere (13) . Mammalian cell reporter plasmid (ERE) 2 -pS2-Luc encoding a luciferase gene downstream of 2ERE was described in Ref. 14, and the internal control plasmid pCMV␤ was from Clontech.
The genes encoding the evolved hER␣ LBD variants were subcloned into the pCMV5-ER␣ plasmids to reconstitute the full-length hER␣ genes. Briefly the LBD genes were PCR-amplified with primers ER␣LBDCam5F (5Ј-ggc cga cca gat ggt cag tg-3Ј) and ER␣3_ClaI (5Ј-gga tcg att cag act gtg gca g-3Ј, the ClaI restriction site is underlined), and the PCR products were purified using a QIAquick PCR purification kit. The pCMV5-ER␣ plasmid was digested with HindIII, and the 1-kb fragment was purified from a 1% agarose gel. The two purified DNA fragments share an overlap region of approximately 100 bp. Overlap extension PCR was performed to obtain full-length mutant hER␣ genes (10 cycles of 94°C for 1 min and 72°C for 4 min) followed by PCR amplification using primer ER␣_pCMV5_5KpnI (5Ј-ccg gta ccc cat gac cat gac-3Ј, the KpnI restriction site is underlined) and ER␣3_ClaI. The PCR products were then purified, digested with KpnI and ClaI, and ligated into the KpnI-ClaI-digested pCMV5-ER␣ vector.
The LBDs of the wild type hER␣ and the evolved hER␣ variants were also subcloned into pET15b (Novagen) for protein expression in Escherichia coli. Briefly, for each plasmid construct, the LBD gene was amplified from pBD-GAL4 hER␣ (wild type or mutants) with primers ER␣_NdeI_N (5Ј-act gta tcg ccg cat atg gcc gac cag atg-3Ј, the NdeI site is underlined) and ER␣_BamHI_C (5Ј-taa gcg gga tcc tca gac tgt ggc agg gaa-3Ј, the BamHI site is underlined), purified, digested with NdeI and BamHI, and ligated into the NdeI-BamHI-digested pET15b vector.
Library Creation and Screening-Error-prone PCR was used to generate a library of mutagenized LBD fragments consisting of hER␣ amino acids 312-595 using pBD-GAL4 hER␣ as a template and ER␣LBDCam5F and ER␣LBDCam3R (5Ј-tca gac tgt ggc agg gaa acc-3Ј) as primers according to the protocol described elsewhere (15) . The resulting mutagenized LBD fragments were then co-transformed with the pBD-GAL4 hER␣ vector that was digested with BglII and BsaI to form a 94-bp gap into yeast YRG2 cells pretransformed with the pGAD424 SRC-1 plasmid. Yeast transformation was carried out using the lithium acetate/single-stranded carrier DNA/polyethylene glycol protocol (16) .
For library screening, a two-tiered strategy consisting of an agar plate-based selection followed by a 96-well plate-based screening was used. In the selection method, the mutagenized LBD fragments were co-transformed with the BglII-BsaI-digested pBD-GAL4 hER␣ vector into Saccharomyces cerevisiae YRG2 cells harboring pGAD424 SRC-1. The transformed cells were plated on an agar plate containing minimum medium lacking tryptophan, leucine, and histidine and supplemented with an appropriate testosterone concentration. The testosterone concentration was chosen such that yeast cells bearing the parental hER␣ LBD in each round of directed evolution cannot form colonies, whereas yeast cells bearing a variant with 5-10-fold improvement in ligand binding affinity may form colonies. Colonies that formed on the selection plates after incubation at 30°C for 2 days were picked and streaked onto two agar plates containing the same minimum medium as mentioned above, one with and one without testosterone. The colonies appearing on the agar plate with testosterone but not on the agar plate without testosterone were picked and assayed in the 96-well plate to determine their EC 50 values. In the 96-well plate assay, yeast YRG2 cells were grown to log phase (A 600 ϭ 2-5) in synthetic complete minimal medium lacking leucine and tryptophan at 30°C overnight (12-16 h) with shaking. The resulting cell culture was diluted to A 600 ϭ 0.002 in liquid minimal medium lacking leucine, tryptophan, and histidine. Each well in the 96-well plate contained 200 l of diluted yeast cells and 0.2 l of the appropriate ligand at a specific concentration dissolved in pure dimethylformamide or EtOH. 96-well plates were incubated at 30°C for 20 -24 h, and the cell density at 600 nm was measured using a SpectraMax 340 PC plate reader (Amersham Biosciences).
Site-directed Mutagenesis-The single, double, and triple mutants were created using overlap extension PCR and yeast in vivo recombination. Briefly, for each mutation, a pair of mutagenic primers with each containing the desired mutation was prepared and used in combination with two oligonucleotide primers flanking the LBD gene. Each of these two flanking primers contained 20 bp homologous to the linearized pBD-GAL4-Cam vector at its 5Ј-end. Two separate PCRs were carried out, each containing one flanking primer and one mutagenic primer. The two PCR products were purified from a 1% agarose gel after DNA electrophoresis, mixed together in an equal molar ratio, and assembled by a primerless PCR. The assembled products were amplified with the two flanking primers. The resulting PCR product was purified from the gel and cotransformed into yeast YRG-2 cells with the EcoRI-SalI-digested pBD-GAL4-Cam vector to obtain circular plasmids. Plasmids were rescued from yeast using the Zymoprep kit (Zymo Research Corp.) and transformed into E. coli DH5␣ to obtain plasmid DNA with high purity. For single mutants, the wild type LBD gene was used as the template for the overlap extension PCR, while for double and triple mutants, the corresponding single and double mutant LBD genes were used as the template, respectively. DNA sequencing was carried out to confirm the presence of the introduced specific mutations and the absence of PCR-associated random mutations. The sequences of the primers will be provided upon request.
DNA Shuffling and DNA Sequencing-DNA shuffling of the second round hER␣ variants was carried out as described elsewhere (17) . DNA sequencing of the evolved hER␣ variants was carried out as described in Ref. 18 .
Cell Culture and Transfection-Cell culture and transfection were performed as described elsewhere (19) .
Hormone Binding Assays-E. coli BL21(DE3) cells transformed with the pET15b plasmid containing the wild type or mutant hER␣ LBD fragments encoding residues 312-595 were grown at 37°C until A 600 ϭ 0.6. Protein expression was then induced with 0.5 mM isopropyl-␤-Dthiogalactopyranoside at 25°C for 5-7 h. Cells were harvested by centrifugation, resuspended in buffer B (50 mM Tris buffer, pH 8.0, 10% glycerol, and 10 mM ␤-mercaptoethanol) at 10 ml/g of wet cells, and lysed by a French press according to the standard protocol suggested by the manufacturer. The cell debris were separated from the supernatants by centrifugation for 30 min at 10,000 ϫ g. The resulting supernatants were used in all hormone binding assays.
The equilibrium ligand binding assay was performed essentially as described elsewhere (19) except that E. coli cell extracts rather than purified proteins were used in the assays. Relative binding affinity (RBA) measurements were determined as previously reported (20) with slight modifications. The cell extracts containing wild type or mutant hER␣ were diluted to 1 nM in buffer B and incubated with buffer alone or with several concentrations of unlabeled competitor together with 2 or 10 nM [ 3 H]E 2 at 0°C for 16 -24 h. At the end of the incubation, the solutions were processed the same way as in the equilibrium ligand binding assay. The unlabeled competitors were diluted to a 1:1 ratio of dimethylformamide:buffer B to ensure solubility, and the final concentration of dimethylformamide in the solution was 7%.
Molecular Modeling-The hER␣ LBD crystal structure (Protein Data Bank code 1GWR) was imported into MOE (Molecular Operating Environment, Chemical Computing Group Inc., Montreal, Quebec, Canada). Force field MMFF94s was used for all simulations. After fixing all missing residues and atoms manually, hydrogen atoms were added. Two steps of energy minimization were performed, first with all the ␣-carbons fixed and then without constraints. Residue Glu-353 was mutated to Gln using the MOE Rotamer Explorer function, and the rotamer that adopts a similar conformation as the original Glu was selected. Testosterone was built using the MOE Builder function and energy-minimized. This testosterone structure was superimposable with the DHT structure found in the rat AR LBD crystal structure complexed with DHT (Protein Data Bank code 1I37). Testosterone was manually placed into the ligand binding pocket of the mutated hER␣ (E353Q) followed by running the docking program (initial temperature, 5000 K; iteration limit, 8000 cycles; 10 cycles per run; 25 runs). The lowest energy docked conformation was further energy-minimized with atoms more than 10 Å away from the ligand being fixed. A short molecular dynamic simulation was then carried out to release all the energy constraints caused by ligand docking. During the molecular dynamic simulation, the energy-minimized receptor-ligand complex was heated to 310 K at 100 K/ps and equilibrated at 310 K for 20 ps with time steps of 1 fs and atoms more than 10Å away from the ligand being fixed. For the structural comparison between AR and ER, the structures of rat AR (Protein Data Bank code 1I37) 2 and hER␣ (Protein Data Bank 1GWR) were imported into MOE and superimposed based on sequence homology.
RESULTS
Library Screening Using Yeast Two-hybrid System-To isolate human ER␣ variants with altered transcriptional activation (transactivation) activity, we developed an efficient and sensitive high throughput screening method based on the yeast two-hybrid system. In this method, the cDNA encoding hER␣ amino acids 312-595 containing most of the LBD domain (hER␣ amino acids 303-553) and the F domain (hER␣ amino acids 554 -595) was fused to the gene encoding the GAL4 DNA binding domain in plasmid pBD-GAL4-Cam (Stratagene) to form the "bait plasmid" pBD-GAL4 hER␣, and the gene encoding human SRC-1 was fused to the gene encoding the GAL4 activation domain in plasmid pGAD424 (Clontech) to form the "prey plasmid" pGAD424 SRC-1.
Both plasmids were transformed and expressed in S. cerevisiae YRG-2, which contains a GAL4-regulated HIS3 reporter construct on its chromosome. The HIS3 reporter provides strong nutritional selection (only cells expressing HIS3 gene product, which is an essential enzyme in the histidine biosynthesis pathway, can grow in a minimal medium lacking histidine). In the presence of agonistic ligands, the LBD undergoes a conformational change and binds to SRC-1, which brings the GAL4 DNA binding domain and the GAL4 activation domain in proximity, thus activating the transcription of the reporter gene. In general, the cell growth rate is proportional to the strength of the ligand-receptor interaction. In the absence of agonistic ligands, no transcription of reporter genes will occur. The functional interaction of ER␣ LBD with the coactivator SRC-1 is critical for effecting transcription in mammalian cells (5) .
We have validated this yeast two-hybrid-based selection/ screening method using the wild type hER␣ LBD in yeast cells. All experiments were done in the 96-well plates where A 600 (cell density) was measured. First, it was shown that cells bearing plasmids pBD-GAL4 hER␣ and pGAD424 SRC-1 responded to E 2 at a subnanomolar concentration, while cells bearing plasmid pBD-GAL4 ER␣ alone had no response to E 2 up to a micromolar concentration, indicating that the cell growth assay is tripartite ( Fig. 2A) . Second, it was found that the ability of cells bearing plasmids pBD-GAL4 hER␣ and pGAD424 SRC-1 to activate transcription in response to a ligand generally correlated with the RBA of the ligand (E 2 (100) Ͼ 17␣-estradiol (58) Ͼ 2-OH-estradiol (7) Ͼ testosterone (Ͻ0.01) Ͼ progesterone (Ͻ0.001), the RBA values (in parentheses) were taken from Ref. 21 ) with greater response seen with ligands with higher RBAs (Fig. 2B) . These results indicate this selection/screening method is very sensitive and specific. It should be noted that the half-maximal effect concentration (EC 50 , the ligand concentration that causes a half-maximal response) of the wild type hER␣ LBD for E 2 was estimated to be ϳ0.6 nM, which is in good agreement with the reported value of the full-length hER␣ for E 2 binding (12) .
For library screening, we used a two-tiered strategy consisting of an agar plate-based selection followed by a 96-well platebased screening. In the selection method, the mutagenized hER␣ LBD variants were co-transformed with pGAD424 SRC-1 into S. cerevisiae YRG2 and plated on an agar plate containing minimum medium lacking tryptophan, leucine, and histidine and supplemented with a predefined testosterone concentration. To eliminate the false positives caused by mutations resulting in ligand-independent responses, the colonies that appeared on the agar plate were picked with toothpicks and restreaked onto two agar plates, one with testosterone and the other without testosterone. The colonies appearing on the agar plate with testosterone but not on the agar plate without testosterone were picked and assayed in the 96-well plate to determine their EC 50 values. Moreover, to ensure that the improved EC 50 value of a positive variant was plasmid-linked, the plasmid was rescued from the corresponding variant and transformed into fresh YRG-2 cells to confirm that the same EC 50 value could be obtained.
Directed Evolution of hER␣LBD Variants with Increased
Response to Testosterone-In the first round of directed evolution, we used error-prone PCR to introduce random point mutations (one to two amino acid substitutions per gene on average) into the LBD fragment consisting of hER␣ amino acids 312-595. Transformed yeast cells bearing a library of hER␣ LBD variants (ϳ60,000) were plated on minimum medium lacking tryptophan, leucine, and histidine and supplemented with 5 ϫ 10 Ϫ7 M testosterone. Cells bearing the wild type ER␣ LBD were used as a negative control. Fifty-three colonies appearing on the selection plates were picked and streaked on two plates, one with testosterone and the other without testosterone. Three ligand-dependent clones were identified and selected for a quantitative dose-response measurement in 96-well plates in which the cell densities were determined over a range of testosterone concentrations.
Two clones (T7 and T17) showed increased ligand sensitivity and were selected for the second round of directed evolution. Two independent libraries of mutants were created using error-prone PCR. Using the same screening strategy, ϳ120,000 clones result- ing from T7 were grown with 10 Ϫ8 M testosterone, and 19 clones were selected. Three of them (T7-15, T7-16, and T7-18) were identified to be true positives. Similarly ϳ110,000 clones resulting from T17 were grown with 10 Ϫ8 M testosterone, and 20 clones were selected. Two of them (T17-2 and T17-4) were identified to be true positives. As shown in Table I , the EC 50 values of the first round mutants for testosterone were increased more than 39-fold compared with that of the wild type ER LBD, and those of the second round mutants were increased another 6 -20-fold (a total of more than 234 -780-fold).
Transactivation Assay in Mammalian Cells-To determine whether the evolved ER mutants in yeast cells will behave similarly in mammalian cells, we evaluated the transactivation profiles of the full-length wild type hER␣ and hER␣ mutants in response to testosterone in ER-negative human endometrial cancer (HEC-1) cells. Briefly the genes encoding mutant hER␣ LBDs were subcloned into ER expression vector pCMV5 (12) to recreate full-length mutant hER␣ genes containing all the ER domains. HEC-1 cells were then transfected with luciferase reporter plasmid (ERE) 2 -pS2-Luc, the indicated ER expression plasmids, and pCMV␤ internal control plasmid. Luciferase activities were normalized to ␤-galactosidase activity and were expressed relative to the wild type hER␣ activity with 10 Ϫ8 M E 2 , which is set at 100%. Consistent with the dose-response data from yeast cells, the second round mutants were at least 200-fold more sensitive to testosterone than was the wild type hER␣. The dose responses of most of the hER␣ variants to E 2 and testosterone were, overall, in good agreement with their dose response in HEC-1 cells (Table I and Fig. 3) .
To probe whether the mutations would result in a promiscuous receptor, we also evaluated two additional ligands, DHT and progesterone, for the wild type hER␣ and hER␣ mutants (Table I and Fig. 3 ). In both yeast and HEC-1 cells, consistent with the fact that DHT is a more potent androgen than testosterone, both the wild type and mutant receptors showed at least 20-fold higher sensitivity to DHT than to testosterone. Moreover, the second round mutants were more sensitive to DHT than were the first round mutants. Interestingly, all the mutant receptors showed enhanced sensitivity to progesterone with the highest fold-improvement of Ͼ30 (T7-16 in yeast) compared with the wild type receptor, suggesting that the mutations have made the receptors more promiscuous.
It should be noted that differences observed in the transactivation activity of some mutants may reflect differences in their responsiveness to coregulators. Although ER interaction with SRC-1 in a two-hybrid assay was used for the selection of ER mutants in yeast, the constellation of coregulators present in the mammalian HEC-1 cells is quite different from those in yeast.
Identification of Functional Mutations in the Evolved hER␣LBD Variants-To identify the molecular basis of altered ER ligand specificity, we sequenced all the evolved hER␣ LBD variants (Fig. 4) . For the first round variants, T17 had a single mutation, E353Q, whereas T7 had two mutations, E353Q and F461I. Since both variants had a similar ligand dose response to either testosterone or E 2 , F461I was thought to be functionally neutral. For the second round variants, since they all contained only one new mutation compared with their parental genes, the following mutations could be unequivocally identified as responsible for the observed higher testosterone response: G442V, G390D, A569T, and L536H. It is of note that G390D appeared in two mutants from two independent libraries. It should also be noted that DNA shuffling of these second round variants failed to produce a variant with further increased response toward testosterone.
To further investigate the effects of these mutations on ER ligand specificity, a series of single mutants, double mutants, and triple mutants were created using site-directed mutagenesis and assayed in yeast cells. As summarized in Table I and shown in Supplemental Fig. 7 , relative to the wild type hER␣, the single mutant F461I hER␣ showed a 4-fold reduced sensitivity to E 2 and a similar sensitivity to testosterone, whereas the single mutant G390D hER␣ showed increased sensitivity to testosterone and a slightly reduced sensitivity to E 2 . The single mutant G442V hER␣ showed a similar sensitivity to E 2 and at least a 2-fold increased sensitivity to testosterone. This mutant had a moderately elevated basal level response. In comparison, the single mutant L536H hER␣ showed a significantly elevated ligand-independent response and a slightly reduced sensitivity to E 2 . The single mutant A569T hER␣ also showed a similar sensitivity to testosterone and a slightly decreased sensitivity to E 2 . The double mutant G442V/F461I hER␣ showed sensitivities to both E 2 and testosterone similar to the single mutant G442V hER␣. Similarly, the triple mutants E353Q/G390D/ G442V and E353Q/G390D/A569T hER␣ showed transcription potency to both ligands that is similar to that of the double mutant E353Q/G390D hER␣. However, the triple mutant E353Q/G390D/L536H hER␣ had similar sensitivity to E 2 but showed a very high basal level response, which made the estimation of EC 50 value of testosterone impossible. Hormone Binding Assay-To establish whether the improved transactivation potencies of these evolved hER␣ variants toward testosterone were the result of the corresponding changes in ligand binding affinities, we measured the binding affinities of these variants by both direct and competitive hormone binding studies. As summarized in Table I , the binding affinities of the wild type hER␣ and the evolved hER␣ variants for E 2 (K d E ) were determined by a direct hormone binding assay. The K d E of the wild type hER␣ was 0.29 Ϯ 0.02 nM, whereas the evolved hER␣ variants had increased K d values toward E 2 , ranging from 0.44 to 3.53 nM (1.5-12-fold decreased affinity compared with the wild type hER␣).
The RBAs of the wild type hER␣ and the evolved hER␣ variants for testosterone were also determined using a competitive hormone binding assay. On this RBA scale, the affinity of E 2 for the wild type hER␣ is set at 100. The RBA of testosterone for the wild type hER␣ was less than 10 Ϫ4 , and the evolved variants had RBAs for testosterone ranging from 0.5 to 1.5. Based on these data, the binding affinities of the wild type hER␣ and the evolved hER␣ variants for testosterone (K d T ) were calculated. As shown in Table I , all the second round hER␣ variants had close to nanomolar affinities to testosterone with the T7-18 showing the highest affinity (38 nM), which represents Ͼ7,600-fold improvement over that of the wild type hER␣.
DISCUSSION
By using error-prone PCR and a yeast two-hybrid-based high throughput screening method, we isolated five hER␣ variants with significantly enhanced affinities for testosterone. Analysis of these evolved hER␣ variants using transactivation assays in yeast and mammalian cells, in vitro hormone binding assays, and molecular modeling provides some novel insights into the molecular basis of ER ligand specificity and the evolutionary mechanism of nuclear receptors.
Functional Mutations Identified in the Evolved hER␣ Variants
A total of seven hER␣ variants with enhanced response toward testosterone were isolated. These seven mutants contained six distinct point mutations, most of which are nonconservative changes. All these mutations were mapped into the crystal structure of the hER␣-testosterone complex in our molecular modeling studies.
TABLE I

Summary of the responses of mutant estrogen receptor to E 2 , T, DHT, and Pg in yeast and HEC-1 cells
Estrogen receptor hER␣ Variants with Androgen-like SpecificityE353Q-Mutation E353Q was found in all evolved hER␣ variants. The single mutant E353Q hER␣ (T17) resulted in more than 29-fold higher sensitivity to testosterone and ϳ11-fold lower sensitivity to E 2 in yeast transactivation assay. This mutation had been identified as playing an important role in the discrimination between estrogens and androgens by site-directed mutagenesis studies (9) . It was believed that the glutamate of ER (Glu-353), a strong hydrogen bond acceptor, would pair well with the A-ring phenolic group of estrogens (a strong hydrogen bond donor), whereas the corresponding glutamine of AR, a good hydrogen bond donor, would pair well with the good hydrogen bond acceptor 3-keto group of androgens (9).
F461I-The single mutant F461I hER␣ showed a 4-fold reduced sensitivity to E 2 and a similar sensitivity to testosterone compared with the wild type receptor, while the double mutant E353Q/F461I hER␣ (T7) had dose responses to both ligands similar to the single mutant E353Q hER␣ (T17). Moreover hormone binding studies indicated that T7 had an affinity for both E 2 and testosterone similar to T17. Thus, F461I seemed to have no effect on the binding of testosterone to the receptor.
G390D-The single mutant G390D hER␣ had higher sensitivity to testosterone and a 4-fold lower sensitivity to E 2 than the wild type hER␣. In comparison, the single mutant E353Q hER␣ resulted in a ϳ29-fold higher sensitivity to testosterone and ϳ11-fold lower sensitivity to E 2 . However, the double mutant E353Q/G390D hER␣ showed a ϳ2-fold decreased sensitivity to E 2 compared with the wild type hER␣ but a more than 476-fold higher sensitivity to testosterone than the wild type receptor. These results were in good agreement with the ligand binding affinity studies. E353Q/G390D hER␣ had a slightly decreased affinity to E 2 (1.5-fold) relative to the wild type receptor, while E353Q hER␣ had a 14-fold lower affinity than the wild type receptor. Moreover, E353Q/G390D hER␣ had a ϳ16-fold higher affinity to testosterone than did E353Q hER␣ and a ϳ5,680-fold higher than did the wild type receptor. Thus, the positive effect of mutations E353Q and G390D on testosterone was synergistic, whereas when combined, their discordant effects on E 2 were canceled out.
Further molecular modeling studies shed some light on the function of this G390D mutation (Fig. 5A ). In the wild type hER␣, the A-ring phenolic group of E 2 is hydrogen bonded with both Glu-353 and Arg-394. Due to the close proximity of the side chains of Glu-353 and Arg-394 (Ͻ4 Å), the net negative charge of Glu-353 is neutralized by the positive charge of Arg-394. The resulting charge neutral ligand binding pocket binds charge neutral E 2 with more favorable energetics. In T7 and T17, the substitution of glutamate by glutamine at position 353 abolishes the hydrogen bond between the wild type hER␣ and E 2 but establishes a new hydrogen bond with testosterone, resulting in a higher affinity to testosterone and lower affinity to E 2 . However, since glutamine is uncharged, the positively charged Arg-394 confers on the ligand binding pocket a net positive charge, which may destabilize the receptor-ligand interactions. The substitution of glycine by aspartic acid at the neighboring residue 390 in T7-16 and T17-2 provides a negative charge, which may neutralize the positive charge on Arg-394. The combination of mutation G390D and E353Q thus further increases the affinity toward testosterone relative to that of the single mutant E353Q hER␣ and also increases the transactivation activity of the receptor in yeast. In addition, this charge neutral ligand binding pocket may also facilitate the binding of charge neutral E 2 , resulting in increased binding affinity of this mutant for E 2 .
G442V-Compared with the wild type receptor, the single mutant G442V showed a similar sensitivity to E 2 and a slightly increased sensitivity to testosterone but with a moderately elevated basal level response. The double mutant G442V/F461I hER␣ showed the same sensitivities to both E 2 and testosterone as the single mutant G442V hER␣. The K d E of T7-15 (E353Q/F461I/G442V) is less than half that of T7 (E353Q/ F461I), while the K d T of T7-15 is about one-fourth that of T7 (Table I ), indicating that T7-15 can bind E 2 and testosterone much more strongly than T7. In the HEC-1 cell transactivation assays, T7-15 showed a ϳ150-fold increased sensitivity to testosterone and a ϳ4-fold decreased sensitivity to E 2 relative to the wild type hER␣. In comparison, in yeast cell transactivation assays, T7-15 had an increased sensitivity toward both E 2 and testosterone compared with T7. The double mutant E353Q/ G442V hER␣ constructed by site-directed mutagenesis showed the same activity as T7-15 (data not shown), while the double mutant G442V/F461I hER␣ and the single mutant G442V hER␣ displayed elevated basal level responses and similar dose responses relative to the wild type hER␣. Thus, the contribution of mutation G442V to the increased transcription potency toward testosterone is dependent on E353Q.
Mutation G442V itself is far away from the ligand binding pocket (17.1 Å away from the A-ring phenolic group of E 2 as determined from the x-ray crystal structure of hER␣, Protein Data Bank code 1GWR). As shown in Figs. 1A and 5B, this mutation is located at the N terminus of helix 8 and its adjacent residue on helix 8 with its side chain pointing toward the same direction is Phe-445. These two residues form a strong van der Waals interaction between their side chains since the benzene ring of Phe-445 is only 3.5 Å above the indole ring of Trp-393 of helix 5. Furthermore Trp-393 is located next to Arg-394, a residue that plays an important role in ligand-receptor interaction. Since the substitution of a glycine by a valine at position 442 will likely introduce residue clashes between the bulkier valine and Trp-393 (as shown in the rotamer search using MOE), it may affect the van der Waals interaction between Phe-445 and Trp-393, changing the position of Arg-394 and further altering the ligand binding affinity. Interestingly, Eng et al. (22) found that mutation G442E increased the transcription potency to E 2 and 2-methoxyestrone compared with the wild type hER␣ in yeast. We are currently using molecular dynamic simulations to gain further insight into the role of this mutation.
L536H-The single mutant L536H hER␣ showed a significantly elevated basal level response to both E 2 and testosterone while showing a similar sensitivity to testosterone and a slightly reduced sensitivity to E 2 in yeast. The double mutant E353Q/L536H hER␣ (T17-4) showed a 52-fold increased transcriptional potency toward testosterone in HEC-1 cells (versus Ͼ640-fold in yeast) and a ϳ10-fold decreased potency toward E 2 in HEC-1 cells (versus 2-fold in yeast) compared with the wild type hER␣. The double mutant E353Q/L536H hER␣ had a negligible basal level response, whereas the triple mutant E353Q/G390D/L536H hER␣ still had an elevated basal level response.
The substitution of Leu-536 by a proline was found to result in an elevated ligand-independent response (22) . Other types of substitutions, such as L536E containing a negatively charged side chain, L536K containing a positively charged side chain, L536N containing a polar side chain, and L536A or L536G containing a smaller side chain gave the same results (23) . Residue Leu-536 is located at the N-terminal end of helix 12, which contains the AF-2 activation domain of hER␣. It was believed that Leu-536 is critical in coupling the binding of ligand to the modulation of the conformation and activity of hER␣ and that a large hydrophobic residue at position 536 is necessary for ligand-dependent transactivation (23) . Strikingly, our finding suggests that in the presence of mutation E353Q, L536H will increase the transcription potency of the receptor to testosterone while maintaining the receptor in an inactive state in the absence of ligand. Thus, L536H is a contextdependent mutation: only the unique combination of E353Q and L536H increased the testosterone dose response while maintaining a negligible basal level response.
A569T-The single mutant A569T hER␣ also showed a similar sensitivity to testosterone and a slightly decreased sensitivity to E 2 relative to the wild type receptor in yeast. The triple mutant E353Q/F461I/A569T hER␣ (T7-18) showed a ϳ10-fold increased testosterone sensitivity and a ϳ3-4-fold increased E 2 sensitivity relative to the double mutant E353Q/F461I hER␣ (T7) in yeast. This result suggests that A569T plays an important role in ER ligand binding.
Additivity of the Functional Mutations
Since recombining the second round hER␣ variants using DNA shuffling failed to yield a variant with further improved sensitivity and binding affinity to testosterone, we suspected that some of the beneficial mutations might not be additive or cumulative. Thus, we used site-directed mutagenesis to construct a few mutants containing different combinations of these functional mutations. As mentioned above, the introduction of functional mutations into the second round variant E353Q/ G390D hER␣ (T17-2) had little effect on the transcription potency of the receptor since the triple mutants including E353Q/ G390D/G442V hER␣ and E353Q/G390D/A569T hER␣ and the double mutant E353Q/G390D hER␣ had a similar transcription potency for both ligands. Moreover the triple mutant E353Q/G390D/L536H hER␣ had a transcription potency for both ligands that was similar to that of the double mutant E353Q/L536H hER␣. Thus, even though the three functional mutations (G442V, L536H, and A569T) are not in close contact with E353Q or G390D, their effects on ligand specificity are not independent and additive. 
Comparison between the Evolved hER␣ Variants and hAR
Comparison of the x-ray crystal structures of the rat AR (Protein Data Bank code 1I37) and hER␣ revealed a very high degree of structural homology (Fig. 6A ). There are a total of 20 amino acid residues in hER and hAR that interact with the bound ligand (either E 2 or testosterone) (Figs. 1A and 6B ). Of them, only six are identical between hER and hAR, even though 18 are located at the same positions in the threedimensional structures. Most of the residues are hydrophobic and interact with the ligand scaffold primarily through van der Waals interactions, whereas a few residues are polar and form hydrogen bonds to the polar atoms in the ligand. For example, in hER␣, polar residues Glu-353, Arg-394, and His-524 form hydrogen bonds with the hydroxyl groups at both ends of E 2 , while in hAR, residues Gln-711, Arg-752, and Thr-877 form corresponding hydrogen bonds with testosterone. The remaining 17 residues in both receptors, except for hER␣ Thr-347 and hAR Asn-705, are hydrophobic and interact with the ligand scaffold through van der Waals interactions. It should be noted that the number of residues that interact with the ligand may vary depending on the chemical structure of a specific ligand. For example, more residues in hER␣ interact with raloxifene than with E 2 (24).
As mentioned above, mutation E353Q alters the hydrogen bond interaction of hER␣ with estrogens and androgens, and of the five discovered beneficial mutations, E353Q is the only residue that directly interacts with the ligand in hER␣. The other four mutations are not located in the ligand binding pocket in either receptor, and none of them except for F461I has an equivalent residue at the corresponding position in hAR. It should be noted that the corresponding residue for mutation L536H in rat AR is Phe-891, which directly interacts with testosterone through van der Waals interaction.
Taken together, these results suggest that the significantly enhanced androgen specificity and affinity in the evolved hER␣ variants may be obtained through subtle modulation of the van der Waals interactions and probably hydrogen bonds between the receptor and ligand by many residues far away from the ligand binding pocket. Very recently, such long range interactions were also demonstrated to be important in determining the ligand selectivity of human estrogen receptor subtypes (25) . Due to the subtlety and complexity of these long range interactions, it is not surprising that some independently obtained functional mutations are not additive or cumulative in their effect on ligand specificity and affinity.
Implications in Molecular Evolution of Nuclear Receptors
There are six evolutionarily related nuclear receptors for steroid hormones: two for estrogens (ER␣ and ER␤) and one each for androgens (AR), progestins (progesterone receptor), glucocorticoids (glucocorticoid receptor), and mineralocorticoids (mineralocorticoid receptor). Molecular phylogenetic analysis suggests that all these steroid receptors have evolved from an ancestral estrogen receptor through a series of gene duplication and divergence events (26, 27) . Furthermore, a ligand exploitation model was proposed as the evolutionary mechanism for steroid receptors in which the terminal ligand (estrogens) in the steroid biosynthetic pathway is the first for which a receptor (an estrogen receptor) evolves; selection for this hormone also selects for the synthesis of intermediates (e.g. progesterone and testosterone) despite the absence of receptors, and duplicated receptors then evolve affinity for these precursor substances (27) . This model was corroborated by most recent work on the isolation, reconstruction, and characterization of the lost ancestral steroid receptor (28) . Consistent with this model, our directed evolution studies on hER␣ indicate that significantly enhanced androgen affinity could be readily created in the hER␣ LBD by two rounds of random point mutagenesis followed by selection for increased affinity to testosterone. Strikingly, only two mutations are needed to achieve near nanomolar affinity for testosterone, and more strikingly, most functional mutations are not in contact with the ligand. Nevertheless, the only ligand-contacting mutation E353Q does play a key role in conferring androgen affinity. Multiple sequence alignment analyses of ARs and ERs showed that a residue corresponding to Gln-353 is found in all naturally occurring androgen receptors (35 AR sequences from 28 different species, Supplemental Fig. 8A ), whereas this same position harbors a glutamate residue in all naturally occurring estrogen receptors (34 ER␣ sequences from 32 different species and 42 ER␤ sequences from 32 different species; Supplemental  Fig. 8, B and C) . This suggests that evolution of a unique glutamine at this position in the ancestral AR sequence (evolved from an ancient ancestral ER sequence (28)) might have been a key event in the emergence of a receptor that binds testosterone. Furthermore, unlike the naturally occurring ARs or ERs, the laboratory-evolved hER␣ variants exhibited significantly enhanced binding affinity for testosterone and only slightly decreased affinity for E 2 and thus became promiscuous receptors at least as far as estrogens and androgens are concerned. Since members in the steroid receptor family arose from a common ancestor via divergent evolution, such dual ligand class promiscuity might play an important role in the creation of new receptors by providing a head start toward being captured by adaptive evolution with further mutations providing the required specificity toward the newly adopted ligand. Of note, a similar evolutionary mechanism was proposed for the creation of new enzyme activities via divergent evolution (29) .
Conclusions
The outcome of the directed evolution studies described above is five hER␣ variants with up to 7,600-fold improvement in the binding affinity for testosterone (38 -95 nM) and a slightly reduced affinity for E 2 (0.44 -0.9 nM). Such dramatic affinity alteration to testosterone required only two or three mutations, and only one of the five beneficial mutations identified from directed evolution was in direct contact with the ligand. Several of the mutations were synergistic or contextdependent. Structural comparison between these evolved hER␣ variants and hAR indicated that most of the ligandcontacting residues in both receptors are hydrophobic (16 of 20) and are located at the same positions in the crystal structures (18 of 20) . The only ligand-contacting mutation E353Q plays a dominant role in discriminating between E 2 and testosterone. However, subtle changes in the interactions between the receptor and ligand, brought by the mutations far away from the binding pocket, can also significantly affect the ligand affinity. Such in vitro evolution studies provide strong experimental evidence for the ligand exploitation model of steroid receptor evolution and further suggest that both positive and negative selection may operate simultaneously in the evolution of a steroid receptor toward new ligand affinities and that there may be several evolutionary pathways toward the same end.
